Compare Oruka Therapeutics Inc. Common Stock (ORKA) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oruka Therapeutics Inc. Common Stock vs ResMed Inc. — how do they compare? Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.18B), while ResMed Inc. trades at $237 (market cap $32.99B). The key difference: ResMed Inc. is far larger — about 6.4× Oruka Therapeutics Inc. Common Stock's market cap, and ResMed Inc. pays a 1.13% dividend while Oruka Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Oruka Therapeutics Inc. Common Stock for 0 Days and ResMed Inc. for 51 Days on average.
| ORKA | RMD | |
|---|---|---|
Market Cap | $5.18B | $32.99B |
Volume | 490,798 | 1,023,381 |
Sector | Health | Health |
52-Week High | $113.08 | $275.96 |
52-Week Low | $26.19 | $182.82 |
Typical Hold Time | 0 Days | 51 Days |
Enterprise Value | $4.31B | $32.35B |
Dividend Yield | — | 1.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
ResMed (RMD) trades at $235.29, up 0.29% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with 27.2% net margins and consistent earnings beats in recent quarters. Recent news highlights include upcoming Q1 2027 earnings and management presentations at healthcare conferences, while analyst consensus remains positive with a $243.56 price target.
RMD presents a favorable investment case with strong profitability metrics and positive earnings momentum, though elevated valuation ratios and ongoing legal investigations warrant caution. The stock's technical strength supports near-term upside potential toward resistance levels, while fundamental growth drivers in sleep therapy demand provide long-term support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
